Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma

5 Feb 2021

Abstract excerpt

Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, therefore, enable patient stratification. Experimental Design: In this retrospective biomarker study, eligible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Lung Cancer Treatments and Mutations
Share to Occupational and environmental lung diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33547197
DOI: 10.1158/1078-0432.ccr-20-4037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaPMID 33547197Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapySemantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase InhibitionSemantic proximity Read ↗

Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR InhibitionSemantic proximity Read ↗

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 GeneSemantic proximity Read ↗

Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.Semantic proximity Read ↗

BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic PerspectivesSemantic proximity Read ↗

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.Semantic proximity Read ↗

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.Semantic proximity Read ↗

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.